Physician profile
James Morrow
NPI 1093798522
$3,572.43
in general payments reported to CMS, 2019-2025
35 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $864 · 2020: $868 · 2021: $714 · 2022: $640 · 2023: $486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $388 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $388.30 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $635.52 | 2019-2023 | |
| Astellas Pharma US INC | $420.08 | 2019-2023 | Veozah, Myrbetriq |
| Pfizer INC. | $385.72 | 2019-2023 | |
| Glaxosmithkline, LLC. | $290.36 | 2019-2023 | Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $170.39 | 2019-2023 | Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $125.11 | 2019-2022 | |
| Inspire Medical Systems, INC. | $124.91 | 2020 | |
| Lilly USA, LLC | $107.38 | 2019-2023 | Mounjaro |
| Merck Sharp & Dohme LLC | $106.46 | 2019-2021 | |
| Horizon Therapeutics Plc | $100.04 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $99.29 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.23 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $75.34 | 2019-2021 | |
| Amarin Pharma, INC. | $74.44 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $59.00 | 2020-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $58.21 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $56.84 | 2022 | |
| Amgen INC. | $54.52 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $54.50 | 2021 | |
| Novartis Pharmaceuticals Corporation | $54.15 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.64 | 2019-2021 | |
| Eisai INC. | $43.10 | 2020-2021 | |
| Esperion Therapeutics, INC. | $37.56 | 2021 | |
| Bausch Health US, LLC | $34.72 | 2021-2022 | |
| Allergan, INC. | $32.61 | 2020 | |
| Arbor Pharmaceuticals, INC. | $31.01 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $27.10 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.76 | 2021-2022 | |
| Abbott Laboratories | $20.59 | 2023 | Freestyle Libre 2 |
| Exact Sciences Corporation | $17.80 | 2023 | Cologuard Collection Kit |
| Linus Health, INC. | $17.67 | 2022 | |
| Boston Scientific Corporation | $16.02 | 2023 | |
| Ibsa Pharma INC. | $14.89 | 2020 | |
| Upsher-Smith Laboratories LLC | $13.45 | 2020 | |
| Paratek Pharmaceuticals, INC. | $12.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Morrow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.